Dermatology Times (@DermTimesNow) header
Dermatology Times (@DermTimesNow) profile picture

A leading news resource serving dermatology clinicians.

North Olmsted, Ohio
Joined July 2009
Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)Photo by Dermatology Times (@DermTimesNow)
Zasocitinib tops deucravacitinib. 3 years of nemolizumab. New targets in lupus and HS. EADV 2026, at a glance โ†“ hubs.li/Q04FClwb0
1
286
๐Ÿ’ก EXPERT INSIGHTS: How should clinicians interpret cross-trial efficacy data when selecting treatments for alopecia areata? ๐Ÿ”— Read more: Weighing Cross-Trial Data and Patient Timelines in Alopecia Areata Treatment #AlopeciaAreata #JAKInhibitors #HairLoss #Dermatology
1
306
Can AI speed up skin cancer pathways? How many viral "glass skin" TikToks get it wrong? Swipe through EADV 2026 highlights โ†“ hubs.li/Q04FBZn40
1
323
๐Ÿ’ก EXPERT INSIGHTS: Mark G. Lebwohl, MD, discusses anticipated monitoring requirements, the differences between oral and injectable therapies, and how disease severity and patient preferences can guide individualized treatment decisions. ๐ŸŽฅ Watch now: hubs.li/Q04FpLnW0
4
517
๐Ÿ“‰ CLINICAL TRIAL UPDATE: Aclaris Therapeutics' investigational antibody bosakitug failed to meet the primary and secondary efficacy end points in a phase 2 trial for moderate to severe atopic dermatitis. hubs.li/Q04FpG-b0 #Bosakitug #AclarisTherapeutics
2
515
In the latest episode of Don't Be Rash, host Andrew Krakowski, MD, is joined by Joseph Lam, MD, FRCPC, of BC Children's Hospital, to discuss how clinicians can distinguish benign birthmarks from early signs of NF1 and related conditions. hubs.li/Q04FgndW0
351
Pritelivir approved. First joint HS guidelines. Zasocitinib vs deucravacitinib. October in dermatology, at a glance โ†“ hubs.li/Q04F2F9Y0
1
2
11
1,380
How early should clinicians consider biologic therapy for children with atopic dermatitis? Mark G. Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai, discusses the importance of skin barrier protection. hubs.li/Q04FgSJQ0
1
4
834
The latest episode of #DontBeRash is now live! In this episode, host Dr. Krakowski sits down with leading expert Dr. Joseph Lam for a deep dive into how CALM count, size, age, and associated findings separate benign spots from NF1 and its mimics. hubs.li/Q04Fc1Kb0
1
1
388
Can castor oil grow hair? Does face taping prevent wrinkles? Swipe through October's Social Media Mythbusters and top stories โ†“ hubs.li/Q04F2ywk0
1
312